Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study | Zendy

Benjamin Gaborit | Zendy; Éric Dailly | Zendy; Bernard Vanhove | Zendy; Régis Josien | Zendy; Karine Lacombe | Zendy; Vincent Dubée | Zendy; Virginie Ferré | Zendy; Sophie Brouard | Zendy; Florence Ader | Zendy; MarieAnne Vibet | Zendy; Aurélie Le Thuaut | Zendy; Richard Danger | Zendy; Laurent Flet | Zendy; Anne Omnes | Zendy; Laetitia Berly | Zendy; Anne Chiffoleau | Zendy; Alexandra Jobert | Zendy; Odile Duvaux | Zendy; François Raffi | Zendy

Open Access

Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study

Author(s) -

Benjamin Gaborit,

Éric Dailly,

Bernard Vanhove,

Régis Josien,

Karine Lacombe,

Vincent Dubée,

Virginie Ferré,

Sophie Brouard,

Florence Ader,

MarieAnne Vibet,

Aurélie Le Thuaut,

Richard Danger,

Laurent Flet,

Anne Omnes,

Laetitia Berly,

Anne Chiffoleau,

Alexandra Jobert,

Odile Duvaux,

François Raffi

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01237-21

Subject(s) - medicine , pharmacokinetics , pneumonia , placebo , mechanical ventilation , adverse effect , cmax , gastroenterology , pharmacology , pathology , alternative medicine

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research